Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227

被引：0
|
作者：
Reck, Martin [1 ]
Brahmer, Julie R. [2 ]
Lee, Jong-Seok [3 ]
Ciuleanu, Tudor-Eliade [4 ,5 ]
Caro, Reyes Bernabe [6 ]
Nishio, Makoto [7 ]
Urban, Laszlo [8 ]
Audigier-Valette, Clarisse [9 ]
Lupinacci, Lorena [10 ]
Sangha, Randeep [11 ]
Paz-Ares, Luis [12 ]
Borghaei, Hossein [13 ]
O'byrne, Kenneth John [14 ,15 ]
Gupta, Ravi G. [16 ]
Bushong, Judith [16 ]
Li, Li [16 ]
Blum, Steven I. [16 ]
Eccles, Laura [16 ]
Ramalingam, Suresh S. [17 ]
机构：
[1] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
[2] Johns Hopkins Kimmel Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[3] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[4] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[5] Univ Med & Pharm Iulia Hatieganu, Cluj Napoca, Romania
[6] Hosp Univ Virgen Rocio, Inst Biomed Seville, Seville, Spain
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[8] Matrai Gyogyintezet, Matrahaza, Hungary
[9] Hop St Musse, Orientat Oncolog Pole14, Toulon, France
[10] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[11] Cross Canc Inst, Edmonton, AB, Canada
[12] Univ Complutense Madrid, Hosp Univ 12 Octubre, Madrid, Spain
[13] Fox Chase Canc Ctr, Philadelphia, PA USA
[14] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[15] Queensland Univ Technol, Brisbane, Qld, Australia
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
920
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [1] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227.
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Lazio
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep S.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Gupta, Ravi
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [2] 5-year Survival Data in the First-line (1L) Treatment of advanced non-small cell Lung Cancer (mNSCLC) with Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (chemo): Results of the CheckMate 227 Study
    Jaeschke, B.
    Brahmer, J. R.
    Lee, J. S.
    Ciuleanu, T. E.
    Caro, R. B.
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    O'Byrne, K. J.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 98 - 99
  • [3] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Schumann, C.
    Paz-Ares, L.
    Ciuleanu, T. -E
    Lee, J. -S
    Urban, L.
    Caro, Bernabe R.
    Park, K.
    Sakai, H.
    Ohe, Y.
    Nishio, M.
    Pluzanski, A.
    Ramalingam, S. S.
    Brahmer, J. R.
    Borghaei, H.
    O'Byrne, K. J.
    Hellmann, M. D.
    Memaj, A.
    Bushong, J.
    Tran, P.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
  • [4] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Bernabe Caro, Reyes
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Pluzanski, Adam
    Burgers, Jacobus
    Mahave, Mauricio
    Ahmed, Samreen
    Schoenfeld, Adam J.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura J.
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1200 - +
  • [5] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Pluzanski, Adam
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Bushong, Judith
    Tran, Phuong
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [7] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA
    Reinmuth, Niels
    Paz-Ares, Luis
    Ciuleanu, Tudor-Eliade
    Cobo-Dols, Manuel
    Bennouna, Jaafar
    Cheng, Ying
    Mizutani, Hideaki
    Lingua, Alejo
    Reyes, Felipe
    Menezes, Juliana
    Jassem, Jacek
    Protsenko, Svetlana
    Feeney, Kynan
    De la Mora Jimenez, Emmanuel
    Lu, Shun
    John, Thomas
    Carbone, David Paul
    Zhang, Xiaoqing
    Hu, Nan
    Reck, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 163
  • [8] Nivolumab (NIVO) plus ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Caro, R. B.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S3
  • [9] Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227
    Peters, S.
    Penrod, J.
    Li, J.
    Lubinga, S.
    Gupta, R.
    Bushong, J.
    Rizzo, J.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S32 - S33
  • [10] First-Line Nivolumab plus Ipilimumab (NIVO plus IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227
    Borghaei, H.
    Brahmer, J. R.
    Lee, J. -S.
    Ciuleanu, T. -E.
    Caro, R. Bernabe
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    O'Byrne, K. John
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E8 - E9
12345